EcoDrugPlus

Cholinergic Receptor, Nicotinic, Alpha 4b

Ensembl ID : ENSSLDG00000019411
Gene Symbol: CHRNA4B
1 Cross references
193 Possible Orthologues:

Coagulation Factor Ii Thrombin Receptor

Ensembl ID : ENSSLDG00000004302
Gene Symbol: F2R
3 Cross references
216 Possible Orthologues:

Coagulation Factor Iii, Tissue Factor

Ensembl ID : ENSSLDG00000012908
Gene Symbol: F3
3 Cross references
199 Possible Orthologues:

Coagulation Factor X-Like

Ensembl ID : ENSSLDG00000012294
Gene Symbol: LOC111653421
3 Cross references
239 Possible Orthologues:

Coagulation Factor X-Like

Ensembl ID : ENSSLDG00000014961
Gene Symbol: LOC111646835
3 Cross references
239 Possible Orthologues:

Coiled-Coil Domain Containing 6

Ensembl ID : ENSSLDG00000015507
Gene Symbol: CCDC6
3 Cross references
207 Possible Orthologues:

Collagenase 3-Like

Ensembl ID : ENSSLDG00000005699
Gene Symbol: LOC111663530
3 Cross references
277 Possible Orthologues:

Colony Stimulating Factor 1 Receptor

Ensembl ID : ENSSLDG00000003467
Gene Symbol: CSF1R
3 Cross references
63 Possible Orthologues:

Complement C5

Ensembl ID : ENSSLDG00000013490
Gene Symbol: C5
2 Cross references
216 Possible Orthologues:

Corticotropin-Releasing Factor Receptor 1-Like

Ensembl ID : ENSSLDG00000021709
Gene Symbol: LOC111664297
2 Cross references
207 Possible Orthologues:

Cyclin D1

Ensembl ID : ENSSLDG00000002651
Gene Symbol: CCND1
3 Cross references
205 Possible Orthologues:

Cyclin D1

Ensembl ID : ENSSLDG00000013956
Gene Symbol: CCND1
3 Cross references
226 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).